References
1. Gardner R.C., Dams-O'Connor K., Morrissey M.R., Manley G.T. Geriatric traumatic brain injury: epidemiology, outcomes, knowledge gaps, and future direction. J Neurotrauma. 2018; 35 (7): 889–906. DOI: https://doi.org/10.1089/neu.2017.5371
2. Sochocka M., Diniz B.S., Leszek J. Inflammatory response in the CNS: friend or foe? Mol Neurobiol. 2017; 54 (10): 8071–89. DOI: https://doi.org/10.1007/s12035-016-0297-1
3. Gong Z., Liu T., Wan Y., Hang Z., Tong X., Zhang B., Yang H., Zhang X., Zhang L., Jin G. Decreased c-rel activation contributes to aberrant interleukin-2 expression in CD4(+)T cells of aged rats. Mol Immunol. 2014; 61 (1): 1–6. DOI: https://doi.org/10.1016/j.molimm.2014.04.010
4. Rosenberg S.A. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192 (12): 5451–8. DOI: https://doi.org/10.4049/jimmunol. 1490019 PMID: 24907378.
5. Tahvildari M., Dana R. Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases. J Immunol. 2019; 203 (11): 2749–55. DOI: https://doi.org/10.4049/jimmunol.1900733
6. Sun L., Hurez V.J., Thibodeaux S.R., Kious M.J., Liu A., Lin P., Murthy K., Pandeswara S., Shin T., Curiel T.J. Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of IL-17 producing T cells. Aging Cell. 2012; 11 (3): 509–19. DOI: https://doi.org/10.1111/j.1474-9726.2012.00812.x
7. Li M., Lin Y.P., Chen J.L., Li H., Jiang R.C., Zhang J.N. Role of regulatory T cell in clinical outcome of traumatic brain injury. Chin Med J (Engl). 2015; 128 (8): 1072–8. DOI: https://doi.org/10.4103/0366-6999.155094
8. Sennikov S.V., Khantakova J.N. Role of T-cell subpopulations in the immunologic tolerance induction. Immunology. 2017; 38 (4): 239–44. DOI: http://dx.doi.org/10.18821/0206-4952-2017-38-4-239-244
9. Leonov A.V. Cerebral blood flow in severe traumatic brain injuries. General Reanimatology. 2008; 4 (2): 9–13. URL: https://cyberleninka.ru/article/n/mozgovoy-krovotok-pri-tyazhelyh-cherepno-mozgovyh-travmah (in Russian)
10. Failla M.D., Kumar R.G., Peitzman A.B., Conley Y.P., Ferrell R.E., Wagner A.K. Variation in the BDNF gene interacts with age to predict mortality in a prospective, longitudinal cohort with severe TBI. Neurorehabil Neural Repair. 2015; 29 (3): 234–46. DOI: https://doi.org/10.1177/1545968314542617
11. Fomicheva E.E., Shanin S.N., Filatenkova T.A., Serebryanaya N.B. IL-2 and regulation of stress hormones and BDNF neurotropic factor levels after experimental traumatic brain injury (TBI). Medical Immunology (Russia). 2020; 22 (4): 647–56. DOI: https://doi.org/10.15789/1563-0625-IAR-1973 (in Russian)
12. Serebryanaya N.B., Lipatova L.V., Sivakova N.A., Vasilenko A.V. Recombinant human interleukin IL-2 as an agent of antiepileptic therapy. Russian Journal of Immunology. 2014; 8 (3): 723–6. URL: https://www.elibrary.ru/download/elibrary_22813217_25671670.pdf(in Russian)
13. Babichev V.N. Neuroendocrine effect of sex hormones. Advances in physiological sciences. 2005; 36 (1): 54–67. URL: https://www.elibrary.ru/item.asp?id=9139556 (in Russian)
14. Beloshitskiy V.V. Principles of modeling traumatic brain injury in experiment. UNJ. 2008; (4): 9–15. URL: https://cyberleninka.ru/article/n/printsipy-modelirovaniya-cherepno-mozgovoy-travmy-v-eksperimente (in Russian)
15. Saleem B.N., Ghirmay K., Kahase M. In silico comparison of interleukin-2 of Homo sapiens with different species. Pharma Focus: ERIPA. 2011; 14: 32–7. URL: https://www.academia.edu/1153368/N_Saleem_Basha_Kewani_Ghirmay_and_Melles_Kahsase_In_silico_comparison_of_interleukin_2_of_Homo_sapiens_with_different_species_Pharma_Focus_The_journal_of_Eritrean_Pharmaceutical_Association_ERIPA_Vol_14_Dec_10_2011_pp32_37
16. Lo M.J., Kau M.M., Cho W.L., Wang P.S. Aging effects on the secretion of corticosterone in male rats. J Investig Med. 2000; 48 (5): 335–42. PMID: 10979238.
17. de Assis G.G., Gasanov E.V. BDNF and cortisol integrative system – plasticity vs. degeneration: implications of the Val66Met polymorphism. Front Neuroendocrinol. 2019; 55: 100784. DOI: https://doi.org/10.1016/j.yfrne.2019.100784
18. Munoz M.J., Kumar R.G., Oh B.M., Conley Y.P., Wang Z., Failla M.D., Wagner A.K. Cerebrospinal fluid cortisol mediates brain-derived neurotrophic factor relationships to mortality after severe TBI: a prospective cohort study. Front Mol Neurosci. 2017; 10: 44. DOI: https://doi.org/10.3389/fnmol.2017.00044
19. Ostrova I.V., Avrushchenko M.S. Expression of brain-derived neurotrophic factor (BDNF) increases the resistance of neurons to death in the postresuscitation period. General Reanimatology. 2015; 11 (3): 45–53. DOI: https://doi.org/10.15360/1813-9779-2015-3-45-53 (in Russian)
20. Simon D., Nascimento R.I., Filho E.M., Bencke J., Regner A. Plasma brain-derived neurotrophic factor levels after severe traumatic brain injury. Brain Inj. 2016; 30 (1): 23–8. DOI: https://doi.org/10.3109/02699052.2015.1077993
21. Kalish H., Phillips T.M. Analysis of neurotrophins in human serum by immunoaffinity capillary electrophoresis (ICE) following traumatic head injury. J Chromatogr B Analyt Technol Biomed Life Sci. 2010. 15; 878 (2): 194–200. DOI: https://doi.org/10.1016/j.jchromb.2009.10.022
22. Camous X., Pera A., Solana R., Larbi A. NK cells in healthy aging and age-associated diseases. J Biomed Biotechnol. 2012; 195956. DOI: https://doi.org/10.1155/2012/195956
23. Abbas A.K., Trotta E., Simeonov D., Marson A., Bluestone J.A. Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol. 2018; 3 (25): eaat1482. DOI: https://doi.org/10.1126/sciimmunol.aat1482
24. Abel A.M., Yang C., Thakar M.S., Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018; 9: 1869. DOI: https://doi.org/10.3389/fimmu.2018.01869